Document is current

Any future updates will be listed below

Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer

Crossref DOI link: https://doi.org/10.1038/s41571-026-01139-w

Published Online: 2026-03-02

Published Print: 2026-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark